These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26038823)

  • 1. Neuronal Cx3cr1 Deficiency Protects against Amyloid β-Induced Neurotoxicity.
    Dworzak J; Renvoisé B; Habchi J; Yates EV; Combadière C; Knowles TP; Dobson CM; Blackstone C; Paulsen O; Murphy PM
    PLoS One; 2015; 10(6):e0127730. PubMed ID: 26038823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice.
    Hickman SE; Allison EK; Coleman U; Kingery-Gallagher ND; El Khoury J
    Front Immunol; 2019; 10():2780. PubMed ID: 31849963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
    Lee S; Varvel NH; Konerth ME; Xu G; Cardona AE; Ransohoff RM; Lamb BT
    Am J Pathol; 2010 Nov; 177(5):2549-62. PubMed ID: 20864679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency.
    Wu J; Bie B; Yang H; Xu JJ; Brown DL; Naguib M
    Neurobiol Aging; 2013 Dec; 34(12):2843-52. PubMed ID: 23855980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease.
    Fuhrmann M; Bittner T; Jung CK; Burgold S; Page RM; Mitteregger G; Haass C; LaFerla FM; Kretzschmar H; Herms J
    Nat Neurosci; 2010 Apr; 13(4):411-3. PubMed ID: 20305648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis.
    Liu Z; Condello C; Schain A; Harb R; Grutzendler J
    J Neurosci; 2010 Dec; 30(50):17091-101. PubMed ID: 21159979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease.
    Cho SH; Sun B; Zhou Y; Kauppinen TM; Halabisky B; Wes P; Ransohoff RM; Gan L
    J Biol Chem; 2011 Sep; 286(37):32713-22. PubMed ID: 21771791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death.
    Suzuki M; El-Hage N; Zou S; Hahn YK; Sorrell ME; Sturgill JL; Conrad DH; Knapp PE; Hauser KF
    Mol Neurodegener; 2011 Nov; 6():78. PubMed ID: 22093090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway.
    Lee S; Xu G; Jay TR; Bhatta S; Kim KW; Jung S; Landreth GE; Ransohoff RM; Lamb BT
    J Neurosci; 2014 Sep; 34(37):12538-46. PubMed ID: 25209291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice.
    Mattison HA; Nie H; Gao H; Zhou H; Hong JS; Zhang J
    J Neuroimmunol; 2013 Apr; 257(1-2):110-5. PubMed ID: 23499256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglial CX3CR1 production increases in Alzheimer's disease and is regulated by noradrenaline.
    González-Prieto M; Gutiérrez IL; García-Bueno B; Caso JR; Leza JC; Ortega-Hernández A; Gómez-Garre D; Madrigal JLM
    Glia; 2021 Jan; 69(1):73-90. PubMed ID: 32662924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons.
    George C; Gontier G; Lacube P; François JC; Holzenberger M; Aïd S
    Brain; 2017 Jul; 140(7):2012-2027. PubMed ID: 28595357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease.
    Hanzel CE; Pichet-Binette A; Pimentel LS; Iulita MF; Allard S; Ducatenzeiler A; Do Carmo S; Cuello AC
    Neurobiol Aging; 2014 Oct; 35(10):2249-62. PubMed ID: 24831823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RPS23RG1 reduces Aβ oligomer-induced synaptic and cognitive deficits.
    Yan L; Chen Y; Li W; Huang X; Badie H; Jian F; Huang T; Zhao Y; Cohen SN; Li L; Zhang YW; Luo H; Tu S; Xu H
    Sci Rep; 2016 Jan; 6():18668. PubMed ID: 26733416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Glutathione Redox Potential Are Linked to Aβ
    Stapper ZA; Jahn TR
    Cell Rep; 2018 Aug; 24(7):1696-1703. PubMed ID: 30110626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection.
    Chen P; Zhao W; Guo Y; Xu J; Yin M
    Biomed Res Int; 2016; 2016():8090918. PubMed ID: 27429982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent effects of CX3CR1 in a mouse model of mild traumatic brain injury.
    Febinger HY; Thomasy HE; Pavlova MN; Ringgold KM; Barf PR; George AM; Grillo JN; Bachstetter AD; Garcia JA; Cardona AE; Opp MR; Gemma C
    J Neuroinflammation; 2015 Sep; 12():154. PubMed ID: 26329692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.
    Yamamoto M; Kiyota T; Horiba M; Buescher JL; Walsh SM; Gendelman HE; Ikezu T
    Am J Pathol; 2007 Feb; 170(2):680-92. PubMed ID: 17255335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin type 1a receptor deficiency decreases amyloid β-protein generation and ameliorates brain amyloid pathology.
    Liu J; Liu S; Matsumoto Y; Murakami S; Sugakawa Y; Kami A; Tanabe C; Maeda T; Michikawa M; Komano H; Zou K
    Sci Rep; 2015 Jul; 5():12059. PubMed ID: 26154270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.